In a small study of 16 patients with rare cancerous angiosarcoma, tumors in 4 patients responded partially or completely to treatment with the immunotherapeutic agents ipilimumab and nivolumab. Two other patients maintained a stable illness with the drug combination. In some cases, the response to treatment lasted for more than a year, with at least one patient completely eliminating the tumor.
This work was done by researchers at the SWOG Cancer Research Network, a clinical cancer clinic. trial A group funded by the National Cancer Institute (NCI), which is part of the National Institutes of Health (NIH).The results are published in Journal for ImmunoTherapy of Cancer..
The study was led by the Fred Hutchinson Cancer Research Center and Dr. Michael Wagner of the University of Washington. “Angiosarcoma is a rare cancer and there are few beneficial treatment options. Patience “There is a subset of patients who respond persistently to immunotherapy, and if they do, we hope they will live longer and have a better quality of life,” Wagner said. I am.
Angiosarcomas are extremely rare, with approximately 400 new cases reported each year in the United States. tumor It usually occurs on the skin and tends to be very aggressive. Metastases are usually treated with chemotherapy, but the cancer’s response to the treatment is usually short-lived and the mortality rate of angiosarcoma is high.Other isolated reports of angiosarcoma tumors responding to immunotherapy Clinical trialHowever, this work represents the first prospective trial of immunotherapy for the disease.
This task is a combination of ipilimumab and nivolumab for a wide range of rare cancers.These investigational drugs known as Immune checkpoint inhibitorIs offered through a joint R & D agreement between NCI and both drug manufacturers Bristol-Myers Squibb.
Through DART, this drug combination has been tested in 53 cohorts of rare cancer patients, 10 of which are still being tested.Other rare cancers that have been treated with some success in the trial include thyroid tumors and metaplastic breasts. cancer, And neuroendocrine tumors. To date, 773 patients have been enrolled in the study, approaching the ultimate goal of 818 patients. The DART study will be conducted by the SWOG-led NCI-sponsored and NIH-funded National Clinical Trials Network (NCTN).
“Other than DART, it probably took years to start studying angiosarcoma,” says Wagner. “By adding it to DART, we were able to get these results quickly.”
Wagner’s team treated 16 eligible patients with a combination of immunotherapy. Six saw the tumor shrink at least somewhat. Three of these patients met a criterion called partial response to treatment and one met a criterion of complete response. Two more patients had stable tumors after the start of treatment. These two patients are still being treated with a stable illness. Of the 5 patients on trial with primary skin disease of the face or scalp, 3 (60 percent) improved with treatment. This is a subset of patients facing particularly severe odds with current treatments.
Patients taking immune checkpoint inhibitors often experienced side effects, and the therapeutic toxicity of patients in this group was comparable to that seen in other studies with the combination of ipilimumab and nivolumab in sarcoma. Of these patients, 75% reported treatment-related adverse events (side effects) and 25% reported grade 3 or higher treatment-related adverse events.
Michael J Wagner et al, a multicenter phase II study of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma (SWOG S1609, cohort 51): dual anti-CTLA-4 and anti-PD- in rare tumors (DART) 1 blocking sub-study, Journal for ImmunoTherapy of Cancer (2021). DOI: 10.1136 / jitc-2021-002990
Provided by SWOG Cancer Research Network
Quote: The persistent response to immunotherapy seen in rare angiosarcoma tumors (August 13, 2021) is https: //medicalxpress.com/news/2021-08-durable-responses-immunotherapy-rare-angiosarcoma. Obtained from html on August 13, 2021.
This document is subject to copyright. No part may be reproduced without written permission, except for fair transactions for personal investigation or research purposes. The content is provided for informational purposes only.
Durable responses to immunotherapy seen in rare angiosarcoma tumors Source link Durable responses to immunotherapy seen in rare angiosarcoma tumors